RxDoctor Payments Data

Pranshu Bansal, MD

Hematology & Oncology · Mesa, AZNPI 1447548722

Payments from drug & device makers

$500,640in general payments, 2019–2025

Across 996 payments — averaging $502.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$175K
  • Pfizer$51K
  • AbbVie$47K
  • AstraZeneca$34K
  • Regeneron Healthcare Solutions, Inc.$32K
  • Bayer$25K
  • plus $137K from 54 others

What the payments were for

  • Consulting fees$96,18051%
  • Speaking & faculty fees$58,48031%
  • Travel & lodging$15,7288%
  • Food & beverage$18,86210%
  • Education$2810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Radius Health, Inc.33$174,873
Pfizer58$50,552
AbbVie23$46,535
AstraZeneca(2 entities)81$34,059
Regeneron Healthcare Solutions, Inc.33$32,142
Bayer38$24,866
Jazz Pharmaceuticals Inc.18$17,568
Gilead(2 entities)53$16,549
Bristol Myers Squibb53$12,164
Rigel Pharmaceuticals, Inc.31$11,290
Johnson & Johnson(2 entities)59$11,232
Sanofi26$7,281
Seagen Inc.27$7,243
Stemline Therapeutics Inc.9$6,296
Dova Pharmaceuticals2$5,550
E.r. Squibb & Sons, L.L.C.28$4,565
Incyte Corporation24$4,224
Exelixis Inc.16$4,192
Verastem, Inc.5$3,768
Daiichi Sankyo Inc.30$2,851
Karyopharm Therapeutics Inc.8$2,353
Immunomedics, Inc.9$2,348
Beigene USA, Inc.12$2,063
Boehringer Ingelheim5$1,894
Astellas Pharma Global Development1$1,860
Genentech USA, Inc.23$1,655
EMD Serono, Inc.3$1,444
Novartis56$1,283
Epizyme, Inc.2$1,259
Adaptive Biotechnologies Corporation2$1,017
Merck42$771
Beigene, Ltd.1$450
Eisai Inc.18$395
Ipsen Biopharmaceuticals, Inc11$352
Intuitive Surgical4$321
Tersera Therapeutics LLC8$252
Astellas Pharma US Inc12$246
Takeda Pharmaceuticals U.S.A., Inc.11$226
Array Biopharma Inc13$209
Genmab U.S., Inc.7$186
Lilly USA, LLC8$161
Sirtex Medical Inc1$155
AVEO Pharmaceuticals, Inc.7$150
Pharmacyclics LLC, An Abbvie Company6$135
Blueprint Medicines Corporation7$126
Mirati Therapeutics, Inc.6$122
Amgen7$121
Beone Medicines USA, Inc.5$114
Sumitomo Pharma America, Inc.4$100
ADC Therapeutics America, Inc.4$86
Sobi, Inc4$84
Sun Pharmaceutical Industries Inc.4$83
Puma Biotechnology, Inc.5$83
GSK4$78
Merit Medical Systems Inc1$71
Coherus Oncology, Inc.4$70
Springworks Therapeutics, Inc.3$62
Pharmacosmos Therapeutics Inc.2$46
Davol Inc.1$41
Myovant Sciences Inc.2$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$500,640 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$5,711,602
Medicare patients
635
Services billed
294,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib77$902,976
JakafiRuxolitinib Phosphate36$659,214
TagrissoOsimertinib Mesylate38$651,656
RevlimidLenalidomide26$429,172
Lenalidomide28$307,385
VenclextaVenetoclax30$234,848
CalquenceAcalabrutinib Maleate14$159,610
EliquisApixaban101$83,224
XareltoRivaroxaban29$38,925
Abiraterone Acetate27$32,875
OrgovyxRelugolix12$31,982
Imatinib Mesylate12$6,214
Dexamethasone125$2,365
Hydroxyurea77$2,297
Ondansetron OdtOndansetron141$1,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$2,063$902,97677 claims
AstraZenecaTagrisso, Calquence$34,059$811,26652 claims
Incyte CorporationJakafi$4,224$659,21436 claims
Bristol Myers SquibbRevlimid$12,164$429,17226 claims
AbbVieVenclexta$46,535$234,84830 claims
PfizerEliquis$50,552$83,224101 claims
Johnson & JohnsonXarelto$11,232$38,92529 claims
Sumitomo Pharma America, Inc.Orgovyx$100$31,98212 claims
Lilly USA, LLCOlanzapine$161$75156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →